India's stock markets are under pressure from three converging forces: foreign institutional investors pulling out capital, a crude oil price shock, and a weakening rupee. Deepak Shenoy, founder of Capitalmind MF, says investors should look past the short-term turbulence and focus on what the underlying data actually shows.
Foreign institutional investors, commonly called FIIs, have been selling Indian equities at a meaningful pace. FII outflows typically put direct pressure on stock prices and the rupee simultaneously, since selling rupee-denominated assets means converting proceeds back into dollars, which weakens the domestic currency further. That feedback loop is a key part of what is stressing Indian markets right now.
Crude oil adds a second layer of strain. India imports roughly 85 percent of its oil needs, so a spike in global crude prices quickly widens the current account deficit, pushes up fuel and logistics costs across the economy, and adds to inflationary pressure. A weaker rupee compounds this because oil is priced in dollars, making every barrel more expensive in local currency terms.
Why Domestic Flows Are the Stabilising Force
Shenoy points out that domestic institutional investors, including mutual funds backed by retail SIP contributions, have been absorbing a portion of the selling pressure from foreign funds. This dynamic has become more visible in Indian markets over the past few years as retail participation has deepened. When domestic money steps in to buy what foreign investors are selling, it cushions the fall and prevents the kind of sharp dislocations seen in earlier market cycles when domestic participation was thinner.
That cushion has limits, though. If FII outflows accelerate or persist over many months, domestic flows alone may not be enough to hold index levels steady, especially in mid and small cap stocks where liquidity is thinner and the FII footprint smaller but volatility higher.
Where Shenoy Sees Relative Safety
On sector positioning, Shenoy flags pharmaceuticals as a defensive play in this environment. Pharma stocks tend to hold up better during global risk-off phases because their revenues are less tied to economic cycles. Domestic drug demand is relatively inelastic, and Indian pharma exporters earn in dollars, which means a weaker rupee actually improves their realised revenue in rupee terms. That currency tailwind is a practical hedge against the same rupee weakness that hurts other parts of the market.
His broader advice to investors is to resist making portfolio decisions based purely on near-term market moves. Volatility driven by global macro factors, such as FII flows, oil prices, and currency shifts, tends to be episodic. Investors who exit during these phases often miss the recovery that follows once the trigger stabilises.
The current episode fits a recognisable pattern. Global risk appetite tightens, foreign capital flows out of emerging markets including India, the rupee weakens, and domestic headlines amplify the fear. What tends to matter more over a one to three year horizon is whether corporate earnings hold up and whether domestic consumption stays resilient. Neither of those questions is fully answered by a few weeks of FII selling.
For now, the practical signals to watch are the pace of FII outflows, the trajectory of crude oil prices, and any Reserve Bank of India intervention in currency markets. The RBI has historically used its foreign exchange reserves to slow sharp rupee moves, and the size and frequency of that intervention will indicate how much stress policymakers see in the current situation. Investors in rate-sensitive sectors like banking and real estate should also monitor whether the oil and currency shock changes the inflation outlook enough to delay any expected rate cuts.